

## Summary of Studies Supporting USDA Product Licensure

| Establishment Name  | Zoetis Inc.   |
|---|---|
| USDA Vet Biologics<br>Establishment Number                                      | 190   |
| Product Code  | 4993.2B   |
| True Name   | Swine Influenza Vaccine, H1N1 & H1N2 & H3N2, Killed Virus,<br>Erysipelothrix Rhusiopathiae Bacterin |
| Tradename(s) / Distributor or<br>Subsidiary<br>(if different from manufacturer) | FluSure XP/ER Bac Plus - No distributor specified   |
| Date of Compilation<br>Summary  | October 24, 2022  |

## Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

| S4 1 T                        |   |  |
|-------------------------------|---|--|
| Study Type                    | Efficacy  |  |
| Pertaining to                 | Erysipelothrix rhusiopathiae  |  |
| Study Purpose                 | Demonstrate a duration of immunity of at least 20 weeks against   |  |
|                               | Erysipelothrix rhusiopathiae  |  |
| <b>Product Administration</b> |   |  |
| Study Animals                 | Swine   |  |
| Challenge Description         |   |  |
| Interval observed after       |   |  |
| challenge                     |   |  |
| Results                       | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission. No data are published because this study was<br>submitted to USDA-APHIS prior to January 1, 2007, and APHIS<br>only requires publication of data submitted after that date. |  |
| USDA Approval Date            | November 24, 1998   |  |

| G <sub>4</sub> 1 T      |   |
|-------------------------|---|
| Study Type              | Efficacy  |
| Pertaining to           | Erysipelothrix rhusiopathiae  |
| Study Purpose           | Demonstrate effectiveness against Erysipelothrix rhusiopathiae  |
| Product Administration  |   |
| Study Animals           | Swine   |
| Challenge Description   |   |
| Interval observed after |   |
| challenge               |   |
| Results                 | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission. No data are published because this study was<br>submitted to USDA-APHIS prior to January 1, 2007, and APHIS<br>only requires publication of data submitted after that date. |
| USDA Approval Date      | November 24, 1998   |

| Study Type              | Efficacy   |  |
|-------------------------|--|--|
| Pertaining to           | Swine Influenza Virus H1N1   |  |
| Study Purpose           | To demonstrate efficacy against respiratory disease due to Swine<br>Influenza Virus H1N1   |  |
| Product Administration  | Two doses administered intramuscularly   |  |
| Study Animals           | Swine  |  |
| Challenge Description   | Minnesota SIV isolate 01-10597H1 (H1N1)  |  |
| Interval observed after |  |  |
| challenge               |  |  |
| Results                 | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |  |
| USDA Approval Date      | 12FEB2002  |  |

| Study Type                    | Efficacy   |
|-------------------------------|--|
| Pertaining to                 | Swine Influenza A virus  |
| Study Purpose                 | Efficacy against respiratory disease due to Swine Influenza A  |
|                               | H1N1, H1N2, and H3N2   |
| <b>Product Administration</b> |  |
| Study Animals                 |  |
| Challenge Description         |  |
| Interval observed after       |  |
| challenge                     |  |
| Results                       | This product class allows the manufacturer to update<br>microorganisms in this vaccine under expedited procedures to<br>respond to emerging needs. Abbreviated data to support<br>influenza strain updates to the product composition were<br>evaluated by USDA-APHIS and found to be acceptable based on<br>regulations and policies at the time of approval. Full vaccination<br>challenge studies may not have been required for these updates. |
| USDA Approval Date            | Apr 03 2015  |

| Study Type                    | Efficacy  |          |        |        |            |        |              |
|-------------------------------|---|----------|--------|--------|------------|--------|--------------|
| Pertaining to                 | Swine Influenza   |          |        |        |            |        |              |
| Study Purpose                 | Efficacy against respiratory disease due to Swine Influenza   |          |        |        |            |        |              |
|                               | Virus, H3N2   | _        |        |        |            |        |              |
| <b>Product Administration</b> | Intramuscular dose a  | dminis   | stered | two    | weeks ap   | art    |              |
| Study Animals                 | Swine influenza viru  | is serol | ogica  | lly ne | egative co | omme   | rcial pigs 3 |
|                               | weeks of age at adm   | inistrat | ion, 2 | 20 vao | cinates a  | ind 21 | controls     |
| Challenge Description         | Influenza A/Swine/I   | ndiana   | /853/2 | 2012   | H3N2, ao   | lminis | stered 14    |
|                               | days after last vaccir  | nation   |        |        |            |        |              |
| Interval observed after       | Observed daily for 5 days. Lung lesions were evaluated 5 days   |          |        |        |            |        |              |
| challenge                     | after challenge   |          |        |        |            |        |              |
| Results                       | Lung lesions was calculated with >5% lung lesions defined as<br>a positive case<br>Five number summary of Lung Consolidation (%): |          |        |        |            |        |              |
|                               | Treatment   | n        | Min    | Q1     | Median     | Q3     | Max          |
|                               | Controls  | 21       | 1.4    | 12.0   | 16.5       | 19.9   | 34.5         |
|                               | Vaccinates  | 20       | 0      | 0.8    | 6.0        | 9.9    | 15.4         |
|                               | Individual animal da  | ta prov  | vided  | below  | v:         |        |              |
| <b>USDA Approval Date</b>     | 13JUN2016   |          |        |        |            |        |              |

| Control | Control %<br>Lung |
|---------|-------------------|
| ID      | Consolidation     |
| 118     | 1.40              |
| 108     | 8.75              |
| 180     | 9.90              |
| 147     | 10.00             |
| 185     | 11.45             |
| 131     | 12.00             |
| 178     | 13.25             |
| 111     | 15.00             |
| 167     | 15.00             |
| 122     | 16.25             |
| 143     | 16.50             |
| 134     | 17.00             |
| 126     | 17.75             |
| 177     | 19.50             |
| 113     | 19.75             |
| 169     | 19.90             |
| 136     | 20.50             |
| 188     | 23.25             |
| 102     | 24.75             |
| 140     | 28.50             |
| 103     | 34.50             |

| Vaccinate<br>ID | Vaccinate %<br>Lung<br>Consolidation |
|-----------------|--------------------------------------|
| 170             | 0.00                                 |
| 179             | 0.30                                 |
| 187             | 0.45                                 |
| 101             | 0.50                                 |
| 174             | 0.50                                 |
| 104             | 1.15                                 |
| 145             | 1.55                                 |
| 186             | 3.30                                 |
| 127             | 3.80                                 |
| 144             | 5.50                                 |
| 130             | 6.50                                 |
| 112             | 7.50                                 |
| 137             | 7.50                                 |
| 117             | 8.45                                 |
| 123             | 9.25                                 |
| 176             | 10.50                                |
| 107             | 12.20                                |
| 138             | 12.50                                |
| 115             | 13.50                                |
| 172             | 15.45                                |
|                 |                                      |

| Study Type              | Efficacy   |  |
|-------------------------|--|--|
| Pertaining to           | Swine Influenza Virus H3N2   |  |
| Study Purpose           | To demonstrate short term efficacy after vaccination against<br>respiratory disease due to Swine Influenza Virus H3N2  |  |
| Product Administration  | Two doses administered intramuscularly   |  |
| Study Animals           | Swine  |  |
| Challenge Description   | NADC SIV isolate 3 (H3N2)  |  |
| Interval observed after |  |  |
| challenge               |  |  |
| Results                 | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |  |
| USDA Approval Date      | November 15, 2001  |  |

| Study Type                    | Efficacy   |  |
|-------------------------------|--|--|
|                               |  |  |
| Pertaining to                 | Swine Influenza Virus H3N2   |  |
| Study Purpose                 | To demonstrate efficacy 10 weeks after vaccination against   |  |
|                               | respiratory disease due to Swine Influenza Virus H3N2  |  |
| <b>Product Administration</b> | Two doses administered intramuscularly   |  |
| Study Animals                 | Swine  |  |
| Challenge Description         | NADC Swine Influenza Virus Isolate 3 (H3N3)  |  |
| Interval observed after       |  |  |
| challenge                     |  |  |
| Results                       | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |  |
| USDA Approval Date            | 21OCT2003  |  |

| Study Type                    | Safety   |  |
|-------------------------------|--|--|
| Pertaining to                 | All  |  |
| Study Purpose                 | Demonstrate safety under field conditions in piglets   |  |
| <b>Product Administration</b> | Two doses administered intramuscularly   |  |
| Study Animals                 | Swine  |  |
| Challenge Description         |  |  |
| Interval observed after       |  |  |
| challenge                     |  |  |
| Results                       | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |  |
| USDA Approval Date            | February 12, 2002  |  |

| Study Type              | Safety   |
|-------------------------|--|
| Pertaining to           | All  |
| Study Purpose           | Demonstrate safety under field conditions in piglets   |
| Product Administration  | Two doses administered intramuscularly   |
| Study Animals           | Swine  |
| Challenge Description   |  |
| Interval observed after |  |
| challenge               |  |
| Results                 | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |
| USDA Approval Date      | February 12, 2002  |

| Study Type              | Safety   |
|-------------------------|--|
| Pertaining to           | All  |
| Study Purpose           | Demonstrate safety under field conditions in piglets   |
| Product Administration  | Two doses administered intramuscularly   |
| Study Animals           | Swine  |
| Challenge Description   |  |
| Interval observed after |  |
| challenge               |  |
| Results                 | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |
| USDA Approval Date      | February 12, 2002  |

| Study Type              | Safety   |
|-------------------------|--|
| Pertaining to           | All  |
| Study Purpose           | Demonstrate safety under field conditions in pregnant sows   |
| Product Administration  | Two doses administered intramuscularly   |
| Study Animals           | Swine  |
| Challenge Description   |  |
| Interval observed after |  |
| challenge               |  |
| Results                 | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |
| USDA Approval Date      | April 29, 2002   |

| Study Type              | Safety   |
|-------------------------|--|
| Pertaining to           | All  |
| Study Purpose           | Demonstrate safety under field conditions in pregnant sows   |
| Product Administration  | Two doses administered intramuscularly   |
| Study Animals           | Swine  |
| Challenge Description   |  |
| Interval observed after |  |
| challenge               |  |
| Results                 | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |
| USDA Approval Date      | April 29, 2002   |

| Study Type              | Safety   |
|-------------------------|--|
| Pertaining to           | All  |
| Study Purpose           | Demonstrate safety under field conditions in pregnant sows   |
| Product Administration  | Two doses administered intramuscularly   |
| Study Animals           | Swine  |
| Challenge Description   |  |
| Interval observed after |  |
| challenge               |  |
| Results                 | Study data were evaluated by USDA-APHIS prior to product<br>licensure and met regulatory standards for acceptance at the time<br>of submission.<br>No data are published because this study was submitted to<br>USDA-APHIS prior to January 1, 2007, and APHIS only<br>requires publication of data submitted after that date. |
| USDA Approval Date      | April 29, 2002   |